HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
TG Therapeutics (TGTX) PT Raised to $30 at JPMorgan
August 7, 2024 6:17 AM EDTJPMorgan analyst Eric Joseph raised the price target on TG Therapeutics (NASDAQ: TGTX) to $30.00 (from $26.00) while maintaining a Overweight rating.
The analyst comments "Following TGs 2Q results and conference call we are updating our model, with takeaways from the call... More
